Lumida
/IONS
⌘K
Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

IONS
$54.21USD-2.59%-1.44 today

MARKET CAP

9.0B

P/E (TTM)

FWD P/E

DAY RANGE

$54 – $56

52W RANGE

$50
$87

AI Summary

Stalk
StalkMedium

IONS remains below its 50-day and 200-day SMAs after a post-capitulation rally, showing medium-term bullish potential but recent exhaustion at resistance warrants patience. We will stalk for a pullback into the rising 9- and 20-day EMAs to confirm structural support before engaging. Primary downside risk is a break below the 9-day EMA, which would signal deeper weakness.

  • ZANVASTRO FDA approval could drive >$100M peak sales.
  • Tringolza Q2 revenue surged 3× to $19M.
  • Non-GAAP op losses of $425–475M challenge profitability targets.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$810.5M$587.4M$787.6M$705.1M$943.7M
YoY %+11.1%-27.5%+34.1%-10.5%+33.8%
P / Sales5.3x9.1x9.6x7.4x13.4x
EV / Sales6.5x11.9x12.4x10.5x16.2x
Gross Profit, Adj.$799.6M$573.3M$778.5M$693.9M$927.8M
YoY %+11.5%-28.3%+35.8%-10.9%+33.7%
Margin %98.7%97.6%98.8%98.4%98.3%
EV / Gross Profit6.6x12.2x12.6x10.7x16.5x
EBITDA, Adj.$-10.6M$-393.4M$-343.4M$-465.5M$-371.7M
YoY %+93.1%-3602.7%+12.7%-35.5%+20.1%
Margin %-1.3%-67.0%-43.6%-66.0%-39.4%
EV / EBITDA-495.2x-17.8x-28.5x-15.9x-41.2x
EBIT$-30.2M$-410.2M$-353.7M$-475.1M$-381.7M
YoY %+82.5%-1258.9%+13.8%-34.3%+19.7%
Margin %-3.7%-69.8%-44.9%-67.4%-40.4%
EV / EBIT-174.3x-17.1x-27.6x-15.6x-40.1x
Net Income$-28.6M$-269.7M$-366.3M$-453.9M$-381.4M
YoY %+93.6%-843.2%-35.8%-23.9%+16.0%
Net Margin-3.5%-45.9%-46.5%-64.4%-40.4%
EPS (GAAP)-$0.20-$1.90-$2.56-$3.04-$2.38
YoY %+93.7%-850.0%-34.7%-18.8%+21.7%